Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy Feb 24, 2022 | Uncategorized
Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma Jun 15, 2021 | Non-Hodgkin Lymphoma